Loading clinical trials...

Effects of DPP-4 Inhibition on Triglycerides | Clinical Trials | Clareo Health

SUSPENDEDPHASE4

Effects of DPP-4 Inhibition on Triglycerides

Effects of Dipeptidyl Peptidase-4 Inhibition With Saxagliptin on Fasting and Postprandial Triglyceride Concentrations

NCT01527747•Oregon Health and Science University

Summary

The purpose of this study is to test the effects of saxagliptin, a treatment for diabetes, on fasting and post-meal blood triglyceride (blood fat) levels.

Detailed Description

This study is designed to help us understand the effects of DPP-4 inhibition on triglyceride levels before and after eating.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Willing to provide signed written informed consent
•Men and women aged 18-80 years
•Type 2 diabetes (as defined by the ADA - see reference 18)
•Baseline HgbA1c between 6.5% and 8%; HgbA1c 7.5-8.0% among subjects taking sulfonylureas
•Baseline plasma triglyceride concentration between 200 and 700 mg/dl
•Stable diabetes medication regimen for at least 12 weeks prior to study entry
•Taking a statin for at least 8 weeks, unless statin therapy is contraindicated or intolerable
•Treatment with other lipid-lowering medications only if the dose has been stable for \> 8 weeks.
•Non-smoker
•Body mass index \< 45.0 kg/m2
+5 more criteria

Exclusion Criteria

•Transaminase concentrations \> 2 times the ULN. (Mild elevations of AST and ALT will be allowed up to 2x ULN at baseline if there is no evidence of viral hepatitis or intrinsic liver disease. Since many of these subjects may have some degree of hepatic steatosis, a key intervention is the implementation of treatment to lower glucose and triglycerides)
•Estimated creatinine clearance \< 60 ml/min
•Microalbumin-creatinine ratio \> 120
•Alcohol consumption \> 1 drink daily in women and \> 2 drinks daily in men
•Pancreatitis within the preceding 6 months
•Type 1 diabetes
•History of diabetic ketoacidosis (DKA)
•Cardiovascular disease (CAD, stroke, PVD)
•Known human immunodeficiency virus (HIV) infection
•Viral hepatitis
+8 more criteria

Locations (1)

Oregon Health & Science University

Portland, Oregon, United States

Key Dates

Start Date

January 1, 2012

Primary Completion Date

November 1, 2024

Completion Date

December 1, 2024

Last Updated

April 7, 2023

Enrollment

ACTUAL participants

Conditions

Type 2 DiabetesHypertriglyceridemia

Interventions

Saxagliptin

DRUG

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITINGPHASE2

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

NCT07296484

Type 2 DiabetesCortisol Excess

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 7, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effects of DPP-4 Inhibition on Triglycerides

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

iGlarLixi CGM Study in Chinese T2D Individuals After OADs

High Intensity Interval Training and Insulin Sensitivity in Type 2 Diabetes

SGLT2i, Pioglitazone, and Ketone Production in T2D

Closed-loop in Adults With Type 2 Diabetes